Catalent announced on April 21, 2022 that it is planning a multi-year $350 million investment at its facility in Bloomington, Ind. to expand its biologics drug substance and drug product manufacturing capabilities.
The project will include the additions of new 2000-liter single-use bioreactors, syringe filling lines, and additional lyophilization capacity supported by quality control laboratories and complex automated packaging. The packaging space will have high-speed, automated cartoning, and auto-injector device assembly capabilities. These new capabilities are expected to be fully operational later in 2022.